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More than 65 loci, encoding up to 500 different genes, have been implicated by genome-wide association studies (GWAS)
as conferring an increased risk of developing type 2 diabetes (T2D). Whilst mouse models have in the past been central to
understanding the mechanisms through which more penetrant risk genes for T2D, for example, those responsible for neonatal
or maturity-onset diabetes of the young, only a few of those identified by GWAS, notably TCF7L2 and ZnT8/SLC30A8, have to date
been examined in mouse models. We discuss here the animal models available for the latter genes and provide perspectives for
future, higher throughput approaches towards efficiently mining the information provided by human genetics.
1. Introduction
The estimated global prevalence for diabetes in 2011 was 366
million, and the disease is expected to affect 552 million
people by 2030 (Diabetes U.K. figures; [1] accessed 09/01/13).
Type 2 diabetes (T2D) is a complex and multifactorial
disease characterised by impaired insulin secretion and
insulin resistance. Disease risk/progression is determined
by a combination of genetic and environmental factors.
It has been consistently demonstrated that lifestyle factors
are associated with risk of T2D across populations [2–8],
with increased adiposity being the greatest modifiable risk
factor for the disease [9, 10]. Inactivity [3, 11], “bad” diet
[2, 6, 8, 12–14], smoking, and other vices [8, 15, 16] and the
nutritional environment during pre- and postnatal life [17]
also contribute to the risk for developing diabetes.
It has been estimated that 30–70%of T2D riskmay be due
to genetics [18]. Whilst pedigree-based linkage analysis and
the candidate gene approach led to the discovery of highly
penetrant genetic defects which account for the development
of diabetes [19–24], it is the advent of large scale genome-
wide association studies (GWAS) which have led to the
accelerated discovery of risk-variants associated with T2D
[25–34]. Currently, over 60 common risk variants have been
identified [30–34], with a combined disease risk of 5–10%
[34, 35], suggesting the existence of many more as yet
undiscovered loci [34, 36, 37]. Most of the GWAS-identified
associations for T2D have high linkage disequilibrium with
a causal variant with a small effect size; the largest common
variant-signal identified to date is that for TCF7L2,which has
a per allelle odds ratio of 1.35 [27–29].
Most of the common variant signals identified by GWAS
are associated with defective pancreatic islet function, indi-
cating that this is the primary driver for the development of
T2D [34, 38]. However, most of the GWAS signals map to
noncoding regions of the genome,making it difficult to estab-
lish functional links to specific transcripts. As a result, deter-
mination both of (a) the identity of the likely transcript(s)
involved and (b) the mechanisms of actions on disease risk,
require the use of genetically tractable organisms where the
expression of candidate genes can be manipulated at will in
a cell type-specific manner. Of the available models (which
include lower organisms such as C. elegans, D. melanogaster,
etc.), mice arguably represent the best compromise between
ease of genetic manipulation and similarity to man, in terms
of both genome structure and physiology. In this review, we
discuss the use of mouse models to study the contribution of
genetic variations, identified by GWAS, in the TCF7L2 and
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SLC30A8 genes to the development of T2D via their effects
on pancreatic islet function.
2. TCF7L2
2.1. Background. The gene-encoding Transcription 7 Like-2
(TCF7L2, previously called TCF4) is themost important T2D
susceptibility gene identified to date, with genetic variants
strongly associated with diabetes in all major racial groups
[27–29, 39–59]. Signals in this locus are the most consistently
identified across various GWAS and are associated with the
highest elevation of risk of developing adult-onset T2D. Each
copy of the risk T-allele at rs7903146 has an increased odds
ratio for T2D of 1.4-1.5 [60]. Inheritance of the risk allele is
also a useful predictor for the likelihood of conversion from
a state of prediabetes to T2D [61, 62]. Additionally, results
from a small number of studies also indicate that TCF7L2
variation may play an important role in cases of early onset
T2D [63, 64].
TCF7L2 is a member of the TCF family of transcription
factors involved in the control of cell growth and signalling
downstream of wingless-type MMTV integration site family
(Wnt) receptors [65]. Activation of the Wnt pathway leads
to release of 𝛽-catenin from an inhibitory complex and its
translocation to the nucleus, where it bindsTCF7L2 and other
related TCF factors [66]. The function of this transcriptional
complex is context dependent; that is it may act as either a
transcriptional activator or repressor [66].
In recent years, the product of the TCF7L2 gene has
been associated with dysregulated pancreatic 𝛽 cell function
and T2D [25, 27, 28]. Enhanced Wnt signalling has been
shown to lead to proliferation of islets [67] and the pancreatic
epithelium [68]. Whilst loss of 𝛽-catenin signalling has been
shown to lead to pancreatic hypoplasia [69], stabilisation of
𝛽-catenin has been shown to result in the formation of large
pancreatic tumours [70].
Individuals carrying the risk alleles of rs7903146 in the
TCF7L2 gene display lowered insulin secretion [61, 71, 72],
impaired insulin processing [71], and decreased sensitivity
to the incretin glucagon-like peptide 1 (GLP-1) [72, 73]
compared to controls. TCF7L2 message levels were elevated
in T2D patients [72, 74], whilst TCF7L2 protein content was
depressed [75]. The decrease in protein content was asso-
ciated with downregulation of GLP-1 and gastric inhibitory
peptide (GIP) receptor expression and impaired pancreatic 𝛽
cell function [74, 76, 77]. Studies have shown that silencing
of Tcf7l2 gene expression in clonal mouse 𝛽 cell lines [76]
and primary islets [75] leads to increased apoptosis [75] and
impaired 𝛽 cell function [19, 20]. Gene expression analysis
following Tcf7l2 silencing revealed changes in the expression
of a number of genes in mouse pancreatic islets [76], one
of which was Glp1r [73, 78]. TCF7L2 may mediate GLP-1-
induced 𝛽 cell proliferation through activation of the Wnt
signalling pathway [79]. Since GLP-1 is implicated in 𝛽 cell
survival, the increased incidence of apoptosis in TCF7L2-
silenced islets [74, 75] and in individuals carrying the variants
of TCF7L2 [73] is consistent with lowered GLP-1 signalling
[73, 78]. Correspondingly, the diminished insulinotropic
effect of GLP-1 in Tcf7l2-silenced islets may be due,
at least in part, to the lack of cognate receptors on the cell
surface [74].
2.2. Mouse Models for TCF7L2
2.2.1. Whole Body Knockout Model. Prior to its association
with T2D, TCF7L2 was previously best known for its associ-
ation with cancer development [80–82]. Homozygous Tcf7l2
knockout (Tcf7l2 −/−) mice die shortly after birth, with a lack
of stem cells in their intestinal crypts [83]. Newborn Tcf7l2
−/− mice have reduced body weight with significantly lower
blood glucose 3 h postpartum than control littermates, which
is not caused by excessive insulin release but by impaired
carbohydrate and lipidmetabolism in the newborn liver [84].
Heterozygote Tcf7l2 +/− mice display >20% decrease
in body weight compared to wild-type littermates, with
decreased glucose, insulin, fatty acid, triglyceride, and choles-
terol in adult mice [84]. Tcf7l2 +/− mice displayed increased
insulin sensitivity, improved glucose tolerance, and reduced
hepatic glucose output [84, 85]. Improved glucose tolerance
was also observed in heterozygote null mice generated using
zinc finger nucleases [85] and insertion of a loxP site and
FRT-flanked neomycin selection cassette within intron 4
and a loxP site within intron 5 [86], with data from the
latter study also pointing to reduced lipogenesis and hepatic
triglyceride levels and decreased peripheral fat deposition
following exposure to a high fat diet in heterozygote mice
compared to control littermates.
Pancreatic development is grossly normal in Tcf7l2 −/−
mice [83, 84]. This observation and a report suggesting
that TCF7L2 was not expressed in the pancreas [87] led to
the proposal that the principle defect underlying decreased
insulin production in TC- or TT-bearing individuals may
be inadequate production of GLP-1, from gut L-cells [88].
However, evidence for differences in GLP-1 level in indi-
viduals with the common versus the at-risk TCF7L2 allele
is currently absent [89], and patient studies have indicated
that the primary defect lies in pancreatic 𝛽 cells [71, 72,
75]. For this reason, mouse models which allow Tcf7l2 gene
expression to be selectively ablated in the islet were required.
2.2.2. Pancreas KnockoutModel. Weused the Pdx1 promoter-
driven Cre recombinase (PDX1.Cre) deleter strain [90] to
effect deletion in all cells of pancreatic lineage in transgenic
mice with a floxed Tcf7l2 exon 1 to address the question
whether selective deletion of Tcf7l2 in pancreas impairs or
improves glucose homeostasis and insulin secretion [77].
This approach allowed us to detect the potential effects of
Tcf7l2 deletion early in pancreatic development, as TCF7L2
has previously been shown to regulate cell proliferation
during development: the Tcf7l2 −/− mouse exhibited defects
in the accumulation of stem cells in the intestinal crypt
[83]. This approach also offered an advantage over the use
of the commonly deployed rat insulin 2-promoter-driven
Cre recombinase (RIP2.Cre) deleter strain since the latter
also leads to deletion in the central nervous system [91–
93]. Pancreas-specific Tcf7l2 −/− (pTcf7l2) mice showed age-
dependent glucose intolerance by 20 weeks of age when
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challenged with an intraperitoneal glucose bolus [77]. Glu-
cose intolerance was detected from 12 weeks of age when
glucose was administered by the oral route, indicating that
the incretin response was impaired [77]. Tolerance to glucose
introduced by both the oral and intraperitoneal route was
exacerbated in pTcf7l2 mice that were exposed to a high fat
diet, with a concomitant decrease in 𝛽 cell mass [77]. The
latter observation is consistent with observations by Shu and
colleagues in high-fat-fed rats [94], where the authors found
a correlation of Tcf7l2 expression and 𝛽 cell regeneration
from pancreatic ductal cells and may reflect the inability of 𝛽
cells to proliferate or regenerate from progenitor cells in the
absence of functional Tcf7l2. The decreased expression of the
cyclin D1 gene [77] from islets of Langerhans extracted from
20-week-old pTcf7l2 mice may contribute towards the lack of
cell proliferation.
pTcf7l2 −/− islets displayed impaired glucose and GLP-1-
stimulated insulin secretion and decreased expression of the
gene encoding for the GLP-1 receptor [77], consistent with in
vitro human and mouse islet and cell line siRNA-mediated-
silencing experiments [74–76]. Whilst the PDX1.Cre strain
is likely to result in deletion in other (non-𝛽) cell types
[95], we observed no difference in plasma glucagon and
GLP-1 levels and in insulin sensitivity in pTcf7l2 mice [77].
Our preliminary data obtained using a more 𝛽 cell selective
deleter strain (Ins1.Cre; J. Ferrer, B. Thorens, unpublished)
also indicate deficiencies in insulin secretion and glucose
tolerance, suggesting that TCF7L2 plays a critical and cell
autonomous role in the 𝛽 cell compartment.
2.2.3. 𝛽 Cell Knockout Model. Recently, Boj and colleagues
generated a 𝛽 cell Tcf7l2 knockout (𝛽TCF4KO) mouse using
the tamoxifen inducible RIP2.Cre-ERT2 deleter strain [96]
bred against a conditional mouse-bearing Tcf7l2 alleles with
a floxed exon 10 [84]. Although the use of the RIP2.Cre-
ERT2 may affect metabolic phenotype through the expression
of Cre recombinase in islet cells as well as in hypothalamic
neurons [95], it is unclear whether Tcf7l2 expression was
affected in the hypothalamus of 𝛽TCF4KO mice.
𝛽TCF4KO mice on normal or high fat diet displayed
normal glucose tolerance when glucose was introduced by
the intraperitoneal route [84]. There was no difference in
plasma insulin and insulin release from isolated islets of
𝛽TCF4KO mice, versus control littermates, in response to
glucose challenge [84]. Importantly, however, mice were not
examined beyond 12 weeks of age, and oral glucose tolerances
were not reported in this later study.
2.2.4. TransgenicModels. In the three previousmousemodels
described in this section, Tcf7l2 gene expression was ablated
either constitutively [83] or specifically in islet cells [77, 84].
Savic and colleagues took a different approach whereby they
engineered mice that expressed LacZ under the control of
human bacterial artificial chromosomes (BACs) containing
the genomic interval encompassing the diabetes associated
SNPs (which are intronic) for TCF7L2 [85]. Using this tech-
nique, they demonstrated the presence of enhancer function
in the SNPs-containing region which drives expression in,
for example, intestine and pancreas, but not in adult islets
[85]. Transgenic mice with Tcf7l2 overexpression driven by
the humanBAC sequence exhibited glucose intolerancewhen
placed on a high fat diet [85]. These data are consistent with
that presented byGaulton and colleagues [103] indicating that
the chromatin of the TCF7L2 intronic variant is in an islet-
specific “open” conformation, and reporter assays demon-
strated increased enhancer activity of the at-risk T-allelle
compared with the C-allelle in 𝛽 cell lines.
The discrepancy in data between the various mouse
models could be partly due to the involvement of TCF7L2 in
glucose homeostasis in more than one tissue, and at different
times during development. The Tcf7l2 gene was manipulated
in different ways in the various experimental models and
this may alter the tissue-specific splicing of the gene [104–
107].The expression of different variantsmay lead to different
outcomes in different tissue types [104–107]. Analysis of
glucose homeostasis at different time points during the life
time of the animals and exposure to differing amounts of time
to diets with different fat composition could all contribute to
the differences in observations.
3. ZnT8 (SLC30A8)
3.1. Background. ZnT8 (encoding by the SLC30A8 gene) is a
member of the zinc transporter family (ZnTs) important for
extruding zinc from the cytosol into either the extracellular
space or intracellular organelles [108]. In particular, the
expression of ZnT8 is largely (but not exclusively) restricted
to 𝛼 and 𝛽 cells of the islets of Langerhans, where the
mature protein resides chiefly on the limiting membrane of
dense core secretory granule [97, 109, 110]. Its function thus,
appears to be chiefly to transport Zn2+ from the cytosol
into the granules where, in beta cells, this is required for
insulin crystallisation [111]. By contrast, the role of Zn2+ in
glucagon storage in the pancreatic alpha cell granule is not
fully understood.
From the discovery that a single nucleotide polymor-
phism in the SLC30A8 gene leads to an increased risk of
developing T2D [27, 29], much work has been done to
elucidate the function of the encoded protein and the role
that ZnT8 plays in the pathogenesis of the disease. In con-
trast with the majority of GWAS-identified polymorphisms,
rs13266634 in the SLC30A8 gene encodes the replacement
of Trp for Arg at position 325 (R325W) at the C-terminus
of the protein and is associated with a ∼20% increased
risk of developing T2D per allele [28]. Given the highly
restricted expression pattern of the transporter, hopes have
been raised that ZnT8 may provide an exciting new drug
target to enhance insulin release in diabetic patients.
3.2. Mouse Models Exploring ZnT8/SLC30A8 Function. A
number of mouse models have been generated in order to
elucidate the function of this molecule and its role in the
pathogenesis of diabetes. These include whole body [97, 99–
101] and cell type-specific (𝛼 or 𝛽 cell) [102] ZnT8 knockout
animals. Systemic ZnT8 knockout models have up to now
been investigated by three different groups [97, 99–101].
These studies have revealed gross abnormalities (albeit age
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Table 1: Summary of the major phenotype of the different colonies of ZnT8 KO mice. ZnT8-𝛼KO and ZnT8-𝛽KO for 𝛼 and 𝛽-cell-specific
knockout mice, respectively; GSIS for glucose-stimulated insulin secretion.
Phenotype/model
ZnT8KO-
London
[97]
ZnT8KO-
Toronto [98]
ZnT8KO-
Leuven [99]
ZnT8KO-
Vanderbilt [100]
(129SvEvBrd × C57BL/6J)
ZnT8KO-
Vanderbilt
[101]
(C57BL/6J)
ZnT8-𝛼KO ZnT8-𝛽KO[102]
Glucose tolerance
≤6 weeks D intolerant D intolerant
C intolerant Normal D intolerant Normal Intolerant
12 weeks D intolerant
C normal
D normal
C intolerant Normal
≥18 weeks Normal Normal Normal
Insulin sensitivity Normal Normal Normal Normal Normal
Plasma glucose
D: Elevated
(fasting) at
6wks,
normal
afterwards.
C: Normal
Normal Normal Normal(fasting)
Plasma insulin Decreased Normal Decreased Normal(fasting)
Normal.
(Plasma
glucagon
normal.)
Normal
Islet insulin content
Normal
(glucagon
content was
normal.)
Normal Normal
Insulin secretion
In vivo Reduced
In vitro
Basal
secretion
enhanced
GSIS normal
GSIS
enhanced GSIS normal GSIS reduced GSIS normal
Reduced first
phase
Glucagon secretion Unaffected
Insulin processing Normal Normal
Granule
morphology Abnormal Abnormal Abnormal Normal Normal Abnormal
and gender dependent) in insulin crystallisation and stor-
age [97, 99] (Figure 1(a)), confirming the importance of
ZnT8 in granular zinc accumulation. Nonetheless, significant
differences were apparent both in terms of the regulation
of insulin secretion and whole body glucose homeostasis.
These differences are likely the result of subtle differences in
genetic background, gender, and the age of the animals. Local
environmental factors including diet and gut microbiome
may also play a role [112]. Thus, glucose tolerance was found
to be impaired at an early age (4–6 weeks of age) in three of
these studies but not at an older age (>18 weeks) [97, 99, 100],
suggesting that the penetrance of the phenotype decreases
with age. While insulin sensitivity was unaltered in all of the
studies, defects in insulin secretion were reported in two of
the studies [97, 100]. None of these changes was associated
with altered beta cell mass (Figures 1(b) and 1(c)) These
data support the view that decreased ZnT8 activity is likely
to influence glucose homeostasis in man and may underlie
the defects which increase the risk of developing T2D.
Differences in the phenotype are summarised in Table 1.
Of note, the two recent studies of Pound et al. stress the
importance of the genetic background. In the first [100], the
genetically modified animals were maintained on a mixed
background, while in the second [101], the mice were back-
crossed onto a pure C57BL/6 background. Strikingly, whereas
glucose-stimulated insulin secretion was unaltered in islets
from ZnT8 knockout mice on a pure C57BL/6 background,
islets from mice on the mixed background showed clear
abnormalities in this parameter. Again, plasma insulin was
decreased in the mixed background animals, while it was
foundnormal inmice on a pure background. Since thesemice
were generated and kept in the same animal facility, it seems
reasonable to exclude environmental differences as playing a
role. Instead, these data support the view that background is
a critical determinant of the penetrance of null ZnT8 alleles.
Whether this impacts the preservation of functional 𝛽 cell
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Figure 1: Electron Micrographs and Optical Projection Tomography (OPT) in ZnT8+/+ and ZnT8−/− mice. (a) Transmission electron
microscopy images of isolated islets from ZnT8+/+ and ZnT8−/− male mice at high magnification (scale bar 1mm) reveals the appearance
of rod-shaped core granules in ZnT8−/− cells, indicated by red arrows (𝑛 = 3 mice). Sections were cut and images were acquired by Dr.
Raffaella Carzaniga and Ms. Katrin Kronenberger. (b) Representative three-dimensional OPT projections of whole fixed and permeabilised
pancreas from ZnT8−/− and ZnT8+/+ mice. In red are the insulin positive structures (𝛽 cells). The overall shape of the whole pancreas was
visualized as autofluorescence and is apparent as white/grey shading. Scale bar = 1 cm. (c) Relative (right panel) and absolute (left panel)𝛽-cell
volume (𝑛 = 2 pancreata per genotype).
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mass in the face of differing insulin sensitivities between
the strains, altered intracellular Zn2+ handling, or defective
auto/paracrine Zn2+ signalling between islets cells remains to
be elucidated.
As mentioned above, ZnT8 is present in both 𝛼 and
𝛽 cells such that the systemic knockout model reflects the
impact of deletion from both cell types (and perhaps others
where ZnT8 is expressed at low but detectable levels). The
generation of cell-specific knockout models has therefore
helped in understanding the contribution of each cell type to
the overall phenotype observed. Wijesekara et al. described
both the animal models in a recent paper [102]. Deletion of
ZnT8 selectively from 𝛽 cells (𝛽ZnT8 null mice; using the
RIP2 promoter) led to similar effects on glucose homeostasis
as those observed in the systemic knockout developed by
the same group and by ourselves [97], confirming that
the transporter is required for proper insulin processing,
crystallization, and packaging. However, 𝛽ZnT8 null mice
displayed additional abnormalities in the expression of key
genes required for normal glucose sensing in 𝛽 cells. Whilst
the underlying reasons for this greater penetrance are unclear,
it is possible that changes in intracellular free Zn2+ levels are
more marked in the 𝛽 cell selective model since the 𝛼 cell
complement remains as an efficient sink for Zn2+ release,
thus, more efficiently depleting 𝛽 cell Zn2+. Nonetheless, the
broad similarities between ZnT8 whole body knockout and
the 𝛽-cell-specific mouse model suggest that the phenotype
of the former is primarily a consequence of ZnT8 deletion in
𝛽 and not 𝛼 cells; 𝛼 cell-selective ZnT8 null mouse displayed
unaltered glucose tolerance. However, glucagon secretion
was not measured in these animals under conditions where
the latter is likely to be physiologically important that is
hypoglycaemia. It therefore remains possible that ZnT8 plays
a significant role in the 𝛼 cell, a possibility which awaits
more detailed examination of 𝛼 cell-selective null mice in the
future.
Because T2D is a polygenic disease that is also influenced
by environmental factors, it is important to mention new
studies where ZnT8 knockout animals were maintained on
a high fat content diet (HFD) [98, 99]. In both of these
studies, ZnT8 null mice displayed an increase in body weight
as well as fasting blood glucose and insulin levels compared
to wild type controls. In particular, in one of these studies,
50% of the ZnT8 knockout animals became hyperglycemic
after exposure to HFD, while none of the controls did so
[99]. Each of these studies was performed using animals on
a mixed (sv129/C57BL6) background. On the other hand,
a further recent study using animals backcrossed onto a
C57BL6 background [101] revealed that ZnT8 null animals
were protected against the effects of high fat, again stressing
the likely importance of modifier genes in determining the
final penetrance of the effect. Although it is difficult to pro-
vide a straightforward rationalisation for these differences,
it is noteworthy that sv129 mice are more insulin sensitive
than C57BL6 animals [113], with the latter producing more
insulin in hyperglycemic clamps. It is possible, therefore, that
C57BL6 mice are better equipped to tolerate perturbations in
insulin storage and secretion following ZnT8 deletion.
These data reinforce the idea that mice, at least, are able
to adapt metabolically to the loss of ZnT8 alleles under many
circumstances. However, under metabolic stress, such as in
the case of a diet rich in fat, the impact of defective insulin
storage and or secretion are more apparent at least for mice
on a mixed genetic background.
Whilst complete inactivation of ZnT8 in the mouse has
been useful as a means of understanding the function of
this protein, it is clear that more work needs to be done in
order to elucidate the significance of the diabetes-associated
polymorphism in vivo. At present, knock-inmodels for either
the protective (W325) or risk (R325) forms of ZnT8 are
missing and may be revealing, provided that the impact on
transporter activity is sufficiently large [97]. Of note, such
models would more closely mimic the situation in humans
and help us to better understand themetabolic, signaling, and
other pathways that are altered in tissues which express the
transporter.
4. Perspectives
4.1. Better Mouse Models. A key point to bear in mind in
assessing the usefulness of mouse models is the relative
plasticity displayed by rodents faced with gene deletions.
Thus, differences between the penetrance of mutations in
human genes linked to monogenic forms of diabetes, includ-
ing maturity onset diabetes of the young (MODY), between
humans and mice, are usually observed [114] with the mouse
equivalents showing far less marked disturbances in glycemia
or changes which are seen only after deletion of both alleles.
This clearly reflects the limitations of the use of mice (weight
∼25 g, life expectancy ∼3 years) for comparisons with human
subjects. Nonetheless, and although the phenotypes of the
above murine models are thus often more subtle than the
human counterparts, they remain useful models for the study
of diabetes, allowing single-targeted gene deletions which are
impossible inman. For example, humanpopulationswith dif-
ferent genetic backgrounds have different susceptibility to the
R235W ZnT8 polymorphism. We should not, therefore, find
surprising the results that different genetic backgrounds and
different diet reveal different phenotypes in ZnT8 knockout
models.
The study of knockout mouse models is most useful if
the likely target gene is clearly defined, as is the case when
a SNP lies in an exon and encodes a nonsense or missense
mutation (as for SLC30A8). One of the difficulties in studying
the contribution of the SNPs identified for increased risk
of T2D is that many of the SNPs identified to date mainly
reside in intronic regions. This may be due to the technical
limitations of identifying the disease-causing gene using
current methods for GWAS, or that the disease-inducing
variation may indeed reside in the intronic region of the
gene, whichmay have regulatory function, as may be the case
for TCF7L2 [85]. Frequently, the sequences within the SNP
regions are poorly conserved between mouse and man, for
example, the sequences spanning SNP rs7903146 for TCF7L2
lies within a repetitive element that is absent in mice. One
possibility is to conduct physiological studies in “humanized”
mice [85], but it is difficult to fully replicate the human
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genetic environment in mouse models. Additionally, it is
technically difficult to introduce targeted changes at high
efficiency at precise locations. The emergence of genome
modification technologies such as transcription activator-like
effector nucleases (TALENs) [115–117] can substantially speed
up the making of a tailored mutant animal model for whole
system approaches to study the contribution of risk variants
identified by GWAS to disease progression andmay be useful
in those instances where the region containing the variation
is sufficiently similar to that found in humans. Importantly,
such gene-editing approaches may also facilitate the use of
alternative species (such as the rat or even the pig) whose
physiology more closely resembles that of man.
An additional complication is that disease-causing SNPs
do not exist in isolation. The genetic landscape of each
individualmay play a part in an individual’s risk of developing
a certain disease. For example, the risk of T2D is additive:
the larger the number of risk SNPs present in an individual’s
genome, the higher the risk for the development of T2D
[37, 118–121]. Thus, future animal models may require careful
mapping of the genetic variations present in themodel animal
and the introduction of more than one genetic variation to
model the diabetic phenotype conferred by these combined
genetic variations.
4.2. Gene-Environment Interactions. An individual’s risk of
developing T2D is the product of interaction between the
individual’s genetic constitution and the environment inhab-
ited by the individual. Whilst the contribution of genetic
factors to disease risk is relatively easy to quantify, the impact
of environmental exposure is less easilymeasured in a clinical
setting. Nevertheless, efforts have been made to study the
interactions between some of the known susceptibility loci
for T2D and the environment, and these findings may be
useful for the development of predictionmodels and tailoring
clinical treatment for T2D [122, 123]. For example, for
carriers of the risk allele for TCF7L2, diets of low glycaemic
load [124, 125] and a more intensive lifestyle modification
regime (versus that recommended for nonrisk carriers) [61,
62, 126, 127] have been shown to reduce the risk of T2D.
Meaningful studies for gene-environment interactions will
require samples of sufficient size to increase statistical power
[128] and accurate methods for measuring environmental
exposure, for example, the use of metabolomics to identify
and assess metabolic characteristics, changes, and pheno-
types in response to the environment, diet, lifestyle, and
pathophysiological states. This information will allow the
generation of better risk prediction models and personalisa-
tion/stratification of treatment, the holy grail of GWAS.
4.3. Cancer versus Diabetes (Opposing Mechanisms Hypothe-
sis). One other observation fromGWAS that should bemen-
tioned, as it may have implications on treatment, is the link
between cancer and T2D. There is epidemiological evidence
that links T2D and cancer [129]. A large number of T2D
genes found via GWAS are involved in cell cycle regulation
[34], for example, the T2D association SNP mapping to
chromosome 9p21 in the vicinity of the tumour suppressor
genes CDKN2A and CDKN2B [130–132] and the CDKN2B
regulator ANRIL [133–135]. Recent genetic data suggest that
common genetic variants influence cancer and diabetes in
opposite directions [136, 137].
4.4. Which Genes Do We Study? A fundamental challenge
facing those wishing to determine which of the genes in a
particular locus is responsible for affecting disease risk, and
dissect how this/these act, is the very scale of the problem
(currently more than 500 genes in total to interrogate, with
others emerging) [35] (and McCarthy M, personal commu-
nication). Clearly, new strategies will be required both to pri-
oritise genes and thus developmodels for those most likely to
be involved: assessment of the impact of a particular variant
(odds ratio) as well as expression profile (notably expression
in 𝛽 cells for those genes affecting insulin secretion), and
finally, the likely biological impact of variations in a particular
gene based on published knowledge are all essential to this
process. Further, “experimental filtration” through higher
throughput approaches (e.g., siRNA in 𝛽 cell lines, including
novel human lines [138]) are likely to be needed. Finally, more
high throughput means to inactivate or overexpress genes in
specific tissues in livingmicewithout the need to engineer the
latter via conventional recombination-based engineering of
embryonic stem cells (e.g., through virus-mediated delivery)
[139] and are likely to be increasingly important. A further
challenge is that of understanding how the identified genes
affect disease risk work via different tissues; systems and
computational biology are likely to be highly important here.
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